NCT05011058 · OUTCOME

Overall Survival (OS)

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas · Source last updated 2025-07-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: days
Interval / dispersion: Full Range
Time frame: Up to approximately 3 years

What was measured

Interval of time from the start of study drug treatment to the date of death for any reason. OS was censored at the time of study withdrawal or study termination, whichever was earlier, for patients without reported death.

Analysis population: Intent-to-Treat Analysis Set, defined as all patients who were enrolled into the trial regardless of whether or not they received study treatment. The study was not designed to make formal statistical comparisons of OS between cohorts.

Groups in this outcome

Diffuse Large B-Cell Lymphoma

Patients with relapsed or refractory EBV-positive diffuse large B-cell lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD

Extranodal Natural Killer/T-Cell Lymphoma

Patients with relapsed or refractory EBV-positive extranodal natural killer/T-cell lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD

Peripheral T-Cell Lymphoma (Combination Therapy)

Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD

Peripheral T-Cell Lymphoma (Monotherapy)

Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week

Hodgkin Lymphoma

Patients with relapsed or refractory EBV-positive Hodgkin lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD

Post-Transplant Lymphoproliferative Disorders

Patients with relapsed or refractory EBV-positive post-transplant lymphoproliferative disorders treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD

Human Immunodeficiency Virus-Associated Lymphomas

Patients with relapsed or refractory EBV-positive human immunodeficiency virus-associated lymphomas treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD

Other EBV-Positive Lymphomas

Patients with relapsed or refractory EBV-positive lymphomas other than those from the other cohorts treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Diffuse Large B-Cell Lymphoma	9
Extranodal Natural Killer/T-Cell Lymphoma	11
Peripheral T-Cell Lymphoma (Combination Therapy)	38
Peripheral T-Cell Lymphoma (Monotherapy)	10
Hodgkin Lymphoma	8
Post-Transplant Lymphoproliferative Disorders	3
Human Immunodeficiency Virus-Associated Lymphomas	3
Other EBV-Positive Lymphomas	20

Reported measurements

Source class 1

Values in days · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Diffuse Large B-Cell Lymphoma	131	Not reported	29	242	Not reported
Extranodal Natural Killer/T-Cell Lymphoma	243	Not reported	35	517	Not reported
Peripheral T-Cell Lymphoma (Combination Therapy)	221	Not reported	14	730	Not reported
Peripheral T-Cell Lymphoma (Monotherapy)	155	Not reported	41	611	Not reported
Hodgkin Lymphoma	570.5	Not reported	64	1000	Not reported
Post-Transplant Lymphoproliferative Disorders	171	Not reported	36	351	Not reported
Human Immunodeficiency Virus-Associated Lymphomas	108	Not reported	76	296	Not reported
Other EBV-Positive Lymphomas	167.5	Not reported	35	513	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
29
upper Limit
242
value
131
group Id
OG001
lower Limit
35
upper Limit
517
value
243
group Id
OG002
lower Limit
14
upper Limit
730
value
221
group Id
OG003
lower Limit
41
upper Limit
611
value
155
group Id
OG004
lower Limit
64
upper Limit
1000
value
570.5
group Id
OG005
lower Limit
36
upper Limit
351
value
171
group Id
OG006
lower Limit
76
upper Limit
296
value
108
group Id
OG007
lower Limit
35
upper Limit
513
value
167.5

denoms

counts
group Id
OG000
value
9
group Id
OG001
value
11
group Id
OG002
value
38
group Id
OG003
value
10
group Id
OG004
value
8
group Id
OG005
value
3
group Id
OG006
value
3
group Id
OG007
value
20
units
Participants

description

dispersion Type

Full Range

groups

description
Patients with relapsed or refractory EBV-positive diffuse large B-cell lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD
id
OG000
title
Diffuse Large B-Cell Lymphoma
description
Patients with relapsed or refractory EBV-positive extranodal natural killer/T-cell lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD
id
OG001
title
Extranodal Natural Killer/T-Cell Lymphoma
description
Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD
id
OG002
title
Peripheral T-Cell Lymphoma (Combination Therapy)
description
Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week
id
OG003
title
Peripheral T-Cell Lymphoma (Monotherapy)
description
Patients with relapsed or refractory EBV-positive Hodgkin lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD
id
OG004
title
Hodgkin Lymphoma
description
Patients with relapsed or refractory EBV-positive post-transplant lymphoproliferative disorders treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD
id
OG005
title
Post-Transplant Lymphoproliferative Disorders
description
Patients with relapsed or refractory EBV-positive human immunodeficiency virus-associated lymphomas treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD
id
OG006
title
Human Immunodeficiency Virus-Associated Lymphomas
description
Patients with relapsed or refractory EBV-positive lymphomas other than those from the other cohorts treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD
id
OG007
title
Other EBV-Positive Lymphomas

param Type

MEDIAN

population Description

Intent-to-Treat Analysis Set, defined as all patients who were enrolled into the trial regardless of whether or not they received study treatment. The study was not designed to make formal statistical comparisons of OS between cohorts.

reporting Status

POSTED

time Frame

Up to approximately 3 years

title

Overall Survival (OS)

type

SECONDARY

unit Of Measure

days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice